Fiduciary Alliance LLC Purchases 1,805 Shares of Humana Inc. $HUM

Key Points

• Fiduciary Alliance LLC has increased its holdings in Humana Inc. by 34.9%, adding 1,805 shares for a total of 6,976 shares valued at approximately $1.705 million.
• Humana's stock ratings have varied, with Bank of America raising its price target from $285.00 to $312.00 and Wall Street Zen downgrading the stock from "buy" to "hold."
• Humana recently announced a quarterly dividend of $0.885, with a dividend yield of 1.3%, which will be paid on October 31st.

Fiduciary Alliance LLC raised its holdings in Humana Inc. (NYSE:HUM - Free Report) by 34.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 6,976 shares of the insurance provider's stock after acquiring an additional 1,805 shares during the quarter. Fiduciary Alliance LLC's holdings in Humana were worth $1,705,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock worth $3,697,222,000 after buying an additional 1,143,662 shares during the period. Dodge & Cox boosted its stake in Humana by 5.5% during the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock worth $2,845,830,000 after acquiring an additional 557,175 shares in the last quarter. Pzena Investment Management LLC boosted its stake in Humana by 6.1% during the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock worth $1,013,133,000 after acquiring an additional 219,541 shares in the last quarter. Davis Selected Advisers boosted its stake in Humana by 3.3% during the first quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider's stock worth $616,873,000 after acquiring an additional 74,434 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its stake in shares of Humana by 1.6% in the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider's stock valued at $327,293,000 after buying an additional 19,613 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

Humana stock traded down $12.47 during midday trading on Friday, reaching $252.39. 4,954,304 shares of the stock were exchanged, compared to its average volume of 1,750,315. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $324.38. The firm has a market cap of $30.36 billion, a PE ratio of 19.37, a PEG ratio of 1.58 and a beta of 0.44. The company's fifty day moving average is $268.12 and its 200-day moving average is $257.41.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The company had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. During the same period in the prior year, the firm earned $6.96 EPS. Humana's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. Humana's dividend payout ratio (DPR) is currently 27.17%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HUM. Barclays raised their price objective on shares of Humana from $275.00 to $315.00 and gave the company an "equal weight" rating in a research note on Friday, September 5th. Wells Fargo & Company dropped their price target on shares of Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a research report on Thursday, August 14th. Royal Bank Of Canada raised their price target on shares of Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a research report on Thursday, August 21st. Piper Sandler dropped their price target on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Finally, Bank of America raised their price target on shares of Humana from $285.00 to $312.00 and gave the company a "neutral" rating in a research report on Tuesday, September 2nd. Seven investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. According to MarketBeat, Humana currently has a consensus rating of "Hold" and a consensus price target of $289.24.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.